Biopharma Cold Chain Logistics Market Size, Share, Growth, Trends, and Global Industry Analysis: By Component (Storage (Warehouse, Refrigerated Container), Transportation (Sea Freight Logistics, Air Freight Logistics, Overland Logistics), Monitoring Components (Hardware (Sensors, RFID Devices, Telematics, Networking Devices) Software) and Region Forecast 2021-2032

Biopharma Cold Chain Logistics Market is valued at US$ 21.0 billion in 2025 and is expected to reach US$ 34.3 billion by 2032, growing at a significant CAGR of 7.3% from 2026-2032. The Spending on biopharma cold logistics has increased over the years. The COVID-19 pandemic has further fueled the growth of biopharma cold logistics, especially for vaccine transport, as vaccines require storage in cold temperatures. The sensitivity of vaccines and cell and gene therapy products to temperature makes cold chain logistics a crucial aspect of their transportation and protection.

With more than 2,000 clinical trials being conducted for cell and gene therapies, it is expected that at least 10 to 20 cell and gene-based therapies will enter the market in the coming years, which will require storage at -150 C. This will further emphasize the importance of biopharma cold chain logistics.

Companies like UPS Healthcare are leveraging smart label technology and other monitoring devices to track various factors such as temperature, light, humidity, vibration, and duration of every door event. This data is then sent via cloud platforms to gain better end-to-end visibility and product stability. Such monitoring systems are applied to entire cargo, individual pallets, and other packages, making biopharmaceutical cold logistics even more efficient and reliable.